WALTHAM, Mass. – November 10, 2016 – Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced the first patient was dosed in a Phase 1 clinical study evaluating a single administration of investigational drug vonapanitase delivered immediately following angioplasty to patients with peripheral artery disease (PAD).
WALNUT CREEK, Calif., Nov. 7, 2016 /PRNewswire/ — Providence Medical Technology, Inc., an innovator in tissue-sparing cervical fusion technology, today announced the commercial launch of its new CAVUX Cervical Cage-L and DTRAX Spinal System-L.
EMERYVILLE, Calif., Sept. 21, 2016 /PRNewswire/ — Mercator MedSystems today announced that 13-month data from the DANCE trial was presented during a late-breaking scientific session at the Vascular Interventional Advances (VIVA) Annual Conference 2016 in Las Vegas, Nevada. DANCE is a prospective, multicenter, single-arm study designed to assess the clinical performance of the localized delivery of a generic steroid, dexamethasone, to the tissues around arteries that have been injured during endovascular interventions, using Mercator’s proprietary Bullfrog® Micro-Infusion Device.
Walnut Creek, CA (May 20, 2016) ‐‐ Providence Medical Technology, Inc., an innovator in tissue- sparing cervical fusion technology, today announced that its two-year radiographic and clinical outcomes data of posterior cervical fusion using an expandable implant are being presented at Spine Week 2016 in Singapore.
ALLENDALE, N.J.–(BUSINESS WIRE)–Stryker’s Spine division today announced the acquisition of the SafeWire product portfolio, including the Y-Wire guidewire and Tiger Jamshidi Needle Family for use in minimally invasive spine surgery. The acquisition is highly complementary to Stryker’s current spine product portfolio and is aligned with the Spine division’s strategy of expanding its product offering for minimally-invasive spine surgery.
EMERYVILLE, Calif., Jan. 21, 2016 – Mercator MedSystems, Inc., has announced their first patient enrollment from Bad Krozingen, Germany, in the company’s LIMBO-PTA clinical trial. This trial combines localized drug delivery using the company’s proprietary Bullfrog® Micro-Infusion Device of an off-the-shelf anti-inflammatory steroid (dexamethasone) with angioplasty. The study measures the benefit of adding drug delivery to the catheter-based re-opening of arteries below the knee in patients suffering from critical limb ischemia (CLI).
LAFAYETTE, Calif. — October 13, 2015 — Providence Medical Technology, Inc., an innovator in tissue-sparing cervical spine technology, today introduced its proprietary CavuxTM surface technology, designed to speed bone fusion during the healing process. The company’s portfolio of DTRAX® Cervical Cage implants will be available with Cavux, a unique surface technology that produces micro-textures on titanium surfaces. The micro- and nano- textures created across the implant surface area serve to enhance the fusion process.
LAFAYETTE, Calif. — August 26, 2015 — Providence Medical Technology, Inc., an innovator in tissue-sparing cervical spine technology, today announced the closing of $12 million in new financing for the company. The proceeds will be used to further commercialize and expand its portfolio of DTRAX® cervical fusion products designed to help patients suffering from cervical degenerative disc disease.
Lafayette, CA (May 29, 2015) ‐‐ Providence Medical Technology, Inc. today announced the full commercial launch of DTRAX Bone Screws in the U.S. market.
“This release represents an important step in broadening our platform of innovative, single-use instruments and implants for cervical fusion,” commented Jeff Smith, Chief Executive Officer of Providence Medical Technology. “Cervical fusion and indirect decompression with DTRAX products offers a compelling, tissue-sparing option for patients suffering from cervical radiculopathy.” Continue Reading